PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
46.94
+1.86 (4.13%)
Apr 15, 2025, 4:00 PM EDT - Market closed
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for PTC Therapeutics stock have an average target of 63.77, with a low estimate of 42 and a high estimate of 113. The average target predicts an increase of 35.85% from the current stock price of 46.94.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PTC Therapeutics stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 4 | 5 | 5 | 6 | 6 | 6 |
Hold | 4 | 3 | 3 | 2 | 3 | 3 |
Sell | 1 | 1 | 1 | 1 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 | 2 |
Total | 13 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Buy Maintains $78 → $75 | Buy | Maintains | $78 → $75 | +59.78% | Mar 31, 2025 |
JP Morgan | JP Morgan | Buy Maintains $72 → $78 | Buy | Maintains | $72 → $78 | +66.17% | Mar 14, 2025 |
B of A Securities | B of A Securities | Sell → Hold Upgrades $41 → $55 | Sell → Hold | Upgrades | $41 → $55 | +17.17% | Mar 11, 2025 |
Scotiabank | Scotiabank | Hold Initiates $55 | Hold | Initiates | $55 | +17.17% | Mar 7, 2025 |
Morgan Stanley | Morgan Stanley | Buy Initiates $67 → $70 | Buy | Initiates | $67 → $70 | +49.13% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
734.57M
from 806.78M
Decreased by -8.95%
Revenue Next Year
858.89M
from 734.57M
Increased by 16.92%
EPS This Year
-3.05
from -4.73
EPS Next Year
-2.24
from -3.05
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 813.7M | 1.0B | 1.7B | ||
Avg | 734.6M | 858.9M | 1.1B | ||
Low | 642.5M | 708.7M | 816.8M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 0.9% | 39.1% | 92.8% | ||
Avg | -9.0% | 16.9% | 29.5% | ||
Low | -20.4% | -3.5% | -4.9% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 7.22 | 5.93 | 9.50 | ||
Avg | -3.05 | -2.24 | -0.08 | ||
Low | -7.44 | -7.22 | -6.32 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.